Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE Trial
Evidence-Based GI: An ACG Publication and Podcast - En podcast av American College of Gastroenterology - Onsdagar
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease,” by Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. N Engl J Med 2024;391:213-223.
